Lyka Labs Limited (LYKALABS) AI Stock Analysis

• Market Cap: ₹3.39B
• Dividend Yield: N/A
• Average Volume (3M): 2.74K
• Price to Earnings (P/E): 45.2
• Beta (1Y): 1.05
• Revenue Growth: 19.40%
• EPS Growth: 1286.88%
• Country: IN
• Employees: 423
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.26
• Shares Outstanding: 35,690,000
• 10 Day Avg. Volume: 4,119
• 30 Day Avg. Volume: 2,739
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹115.00
• Price Target Upside: 21.00% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 58 Neutral
• Price Target: ₹115.00 ▲(21.00% Upside)

The overall stock score of 57.6 reflects strong financial performance with revenue growth and operational improvements but is offset by high valuation and challenges in cash flow management. Technical indicators present mixed signals, indicating caution in the short term.

Lyka Labs Limited Business Overview & Revenue Model

Company Description

Lyka Labs Limited, a pharmaceutical company, engages in development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, muscle relaxant, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. In addition, it provides products and services in therapeutic categories, such as intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetologist, urology, wound care, and anesthesia, as well as deals in pharmaceutical products. The company offers its products in various formulations, including injections, creams, ointments, gels, and lotions. It also exports its products to Bangladesh, Combodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam. Lyka Labs Limited was incorporated in 1976 and is based in Mumbai, India.

How the Company Makes Money

Lyka Labs Limited generates revenue through the sale of its pharmaceutical products, which include both generic and specialty drugs. The company's key revenue streams consist of domestic and international sales of finished pharmaceutical formulations and active pharmaceutical ingredients (APIs). Lyka Labs has established distribution networks and partnerships with healthcare providers, pharmacies, and other pharmaceutical companies to expand its market reach. Additionally, the company invests in research and development to innovate and introduce new products, thereby enhancing its competitive edge and revenue potential. Strategic alliances and collaborations with other entities in the healthcare sector also contribute to its earnings by expanding its product offerings and market presence.

Lyka Labs Limited Financial Statement Overview

Summary

Lyka Labs Limited shows strong revenue growth and improved operational efficiency with better EBIT and EBITDA margins. The balance sheet has strengthened with increased equity and reduced leverage, though high liabilities pose risks. Cash flow management is challenging, with negative free cash flow affecting flexibility.

Income Statement

Lyka Labs Limited has shown strong revenue growth, with a significant increase in Total Revenue from the previous years. The Gross Profit Margin is robust, indicating effective cost management. However, the Net Profit Margin has fluctuated, suggesting varying profitability levels. The EBIT and EBITDA margins have improved, reflecting enhanced operational efficiency over time.

Balance Sheet

The company has improved its financial position with increasing Stockholders' Equity, which has strengthened the Equity Ratio. The Debt-to-Equity Ratio has decreased, indicating reduced leverage. However, the overall liabilities remain high, posing potential financial risks. Return on Equity has improved due to better profitability in recent periods.

Cash Flow

Operating Cash Flow has been relatively stable but remains low compared to Net Income, indicating less cash generation from operations. Free Cash Flow has been negative, primarily due to high capital expenditures. The Free Cash Flow to Net Income ratio highlights challenges in converting profits into free cash flow, which could affect future investments.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.39B	1.41B	1.06B	883.39M	1.84B	671.07M
Gross Profit	737.80M	851.35M	609.92M	507.85M	1.30B	289.23M
EBITDA	204.43M	201.67M	167.59M	128.47M	1.01B	201.17M
Net Income	80.16M	80.12M	-24.89M	-132.12M	390.00M	-115.55M
Balance Sheet
Total Assets	1.76B	1.76B	1.57B	1.52B	1.86B	1.90B
Cash, Cash Equivalents and Short-Term Investments	13.63M	13.63M	62.91M	119.39M	180.20M	76.30M
Total Debt	391.84M	391.84M	586.50M	746.30M	1.30B	1.63B
Total Liabilities	726.24M	726.24M	884.59M	1.06B	1.72B	2.15B
Stockholders Equity	1.04B	1.04B	681.54M	454.41M	133.38M	-257.97M
Cash Flow
Free Cash Flow	0.00	-137.55M	-74.58M	7.67M	717.33M	75.44M
Operating Cash Flow	0.00	18.99M	17.73M	89.53M	792.46M	88.11M
Investing Cash Flow	0.00	-117.96M	-94.88M	73.50M	-61.72M	-1.61M
Financing Cash Flow	0.00	52.92M	19.53M	-216.43M	-631.77M	-117.98M

Lyka Labs Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 95.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LYKALABS, the sentiment is Negative. The current price of 95.04 is below the 20-day moving average (MA) of 99.30, below the 50-day MA of 103.67, and below the 200-day MA of 119.23, indicating a bearish trend. The MACD of -1.57 indicates Positive momentum. The RSI at 28.73 is Positive, neither overbought nor oversold. The STOCH value of 22.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:LYKALABS.

Lyka Labs Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDICO	66 Neutral	₹4.00B	39.66	16.16%	―	4.15%	21.74%
SMSLIFE	61 Neutral	₹3.46B	20.05	10.23%	0.13%	3.34%	-3.38%
LYKALABS	58 Neutral	₹3.39B	45.17	―	―	19.40%	1286.88%
ZIMLAB	54 Neutral	₹3.57B	38.06	4.82%	―	-3.36%	-47.58%
NURECA	48 Neutral	₹2.30B	-76,533.33	0.44%	―	35.84%	-100.52%
BROOKS	42 Neutral	₹4.03B	313.47	-10.16%	―	10.30%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%